BIOLOGICAL SIGNALING AXIS

Growth Hormone Secretagogues & GHRH

Structural and kinetic profiling of synthetic peptides designed to selectively stimulate pulsatile endogenous growth hormone secretion via pituitary receptor pathways.

Indexed Compounds2 CompoundsFull Chemical Dossiers

PubMed Citations6 StudiesPeer-Reviewed Literature

Verification Tier100% HPLC/MSAssayed Reagent Standards

Core Receptor Cascade & Cellular Targets:

GHSR-1a receptor agonism, GHRH receptor selectivity, downstream IGF-1 transcription without prolactin perturbation.

Indexed Compounds in Growth Hormone Secretagogues & GHRH

Select a peptide to review molecular formulas, amino acid sequences, and verified commercial sourcing links.

2 Active Dossiers

CAS 863288-34-0MW: 3367.97

CJC-1295

Modified Growth Hormone Releasing Factor GRF(1-29) Tetrasubstituted

Formula:C152H252N44O42

CJC-1295 is a tetrasubstituted 29-amino-acid synthetic peptide analog of growth hormone-releasing hormone (GHRH). It is designed with substitutions at positions 2, 8, 15, and 27 to impart resistance against dipeptidyl peptidase-4 (DPP-4) enzymatic degradation.

LyophilizedPre-MixedMeteredSynergistic

Inspect Profile & Sourcing

CAS 170851-70-4MW: 711.86

Ipamorelin

Aib-His-D-2-Nal-D-Phe-Lys-NH2 Pentapeptide GHSR Agonist

Formula:C38H49N9O5

Ipamorelin is a synthetic pentapeptide and selective ghrelin/growth hormone secretagogue receptor 1a (GHSR-1a) agonist. It demonstrates exquisite somatotroph selectivity, eliciting endogenous growth hormone pulses without significantly raising adrenocorticotropic hormone (ACTH), cortisol, prolactin, or aldosterone.

LyophilizedPre-MixedMeteredSynergistic

Inspect Profile & Sourcing

Biochemical Architecture

Cellular Signaling Mechanisms & In Vitro Cascades

Phase 1: Receptor Binding

Transmembrane Affinity

Selective binding to primary G-protein coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), or ionotropic complexes initiating intracellular phosphorylation.

Phase 2: Signal Transduction

Second Messenger Activation

Cascade phosphorylation via MAP kinase, PI3K/Akt, or adenylate cyclase pathways, modulating cytosolic calcium levels and nuclear transcription factor recruitment.

Phase 3: Phenotypic Outcome

Transcriptional Synthesis

Upregulation of specific mRNA transcripts for structural proteins, angiogenic mediators, or neurotrophins documented across in vitro and pre-clinical assays.

Peer-Reviewed PubMed Literature Index

Primary publications documenting the molecular kinetics and assays of compounds in this axis.

6 Indexed Studies

CJC-1295The Journal of Clinical Endocrinology & Metabolism (2006)

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I by CJC-1295 in healthy subjects

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.

Key Finding: Demonstrated dose-dependent 2- to 10-fold elevations in GH and 1.5- to 3-fold increases in IGF-1 in human randomized kinetic protocols.

PMID 16352683

CJC-1295Peptides (2005)

Substituted growth hormone-releasing hormone analogs with extended in vivo half-lives

Jetté L, Léger R, Thibaudeau K, Benquet C, et al.

Key Finding: Characterized complete resistance to DPP-4 enzymatic inactivation, resulting in 4-fold greater metabolic stability.

PMID 15862661

CJC-1295Reviews in Endocrine and Metabolic Disorders (2008)

GHRH and its synthetic analogs: Neuroendocrine kinetics and therapeutic investigations

Alba M, Fintini D, Saggese G, Salvatori R.

Key Finding: Analyzed physiological pulsatility preservation and pituitary reserve maintenance under prolonged secretagogue exposure.

PMID 18270830

IpamorelinEuropean Journal of Endocrinology (1998)

Ipamorelin, the first selective growth hormone secretagogue

Raun K, Hansen BS, Johansen PB, Thøgersen H, et al.

Key Finding: Confirmed selective GH release with absolute absence of ACTH, cortisol, or prolactin elevation in in vivo and in vitro paradigms.

PMID 9849822

IpamorelinPharmaceutical Research (1999)

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Gobburu JV, Agersø H, Jusko WJ, Ynddal L.

Key Finding: Established clean linear pharmacokinetics and rapid clearance profiles without accumulation across human cohorts.

PMID 10496660

IpamorelinGrowth Hormone & IGF Research (1999)

Ipamorelin, a new growth-hormone secretagogue, induces longitudinal bone growth in rats

Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, et al.

Key Finding: Quantified significant increase in tibial longitudinal bone growth rate without perturbing plasma IGF-I binding protein profiles.

PMID 10429486

Laboratory Practice

Storage & Reconstitution Parameters for Growth Hormone Secretagogues & GHRH

Lyophilized peptides cataloged in this pathway should be preserved at -20°C in desiccated containment. Upon reconstitution with Bacteriostatic Water or sterile isotonic saline, maintain solutions at 2°C to 8°C. Avoid repetitive freeze-thaw cycles which induce mechanical shearing of tertiary amino acid conformations.

Launch Dilution Calculator·View Full Research Safety Policy

Explore Other Research Pathways

All Pathways

Pathways Directory